Reply to de Vries HE, Van Oijen MGH, de Jong DJ. Safety of infliximab in inflammatory bowel disease needs to be debated. Clin Gastroenterol Hepatol 2009;7:603-604

Sarah Caspersen, Christian Mortensen, Lene Riis, Tine Jess, Flemming Bendtsen

Abstract

Udgivelsesdato: 2009-Nov

Citationsformater